ArticleOncology letters2026
Preliminary study on the efficacy of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma: Real-world data from a single center.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to explore the clinical efficacy and safety of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma (mRCC), providing a reference for clinical decision-making. In the present study, clinical data from 22 patients with mRCC who received pazopanib combined with toripalimab treatment at Shanxi Province Cancer Hospital (Taiyuan, China) were retrospectively collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and drug safety were analyzed. Among the 22 patients (17 men and 5 women), the median age was 63.5 years. In terms of pathological classification, 19 patients (86.4%) had clear cell RCC. The organs with metastasis mainly included the lungs, lymph nodes, bones, liver and brain. According to the International Metastatic Renal Cell Carcinoma Database Consortium risk classification, 13.6% (3 patients) were classified as favorable-risk, 77.3% (17 patients) were classified as intermediate-risk and 9.1% (2 patients) were classified as poor-risk. A total of 6 patients (27.3%) discontinued treatment due to adverse events (AEs), which included hypertension, proteinuria, elevated transaminases and hypothyroidism. The median follow-up time was 14 months (range, 3-24 months). The overall ORR was 36.36% and the DCR was 77.27%. The median PFS time was 17.1 months (range, 5.9-22.6), while the median OS was not reached. Common AEs included fatigue (27.27%), nausea/vomiting (18.18%), diarrhea (31.82%), hypertension (31.82%), proteinuria (22.73%), elevated transaminases (63.64%), hypothyroidism (18.18%), hand-foot skin reaction (22.73%), rash (9.09%) and leukopenia (13.64%). In conclusion, in the present small, single-center, retrospective real-world study, pazopanib combined with toripalimab as first-line therapy for mRCC showed preliminary signs of efficacy with manageable AEs. These real-world observations suggested that the combination may be feasible and warrants further prospective investigation; however, no clinical recommendation can be made based on the present data. Further prospective randomized controlled trials are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.